公开(公告)号：US20250064902A1

公开(公告)日：2025-02-27

申请号：US18914723

申请日：2024-10-14

Applicant: AUROBAC THERAPEUTICS SAS

Inventor： Michael WITTEKIND ,  Raymond SCHUCH

IPC: A61K38/47 ,  A61K9/00 ,  A61K31/7036 ,  A61K38/12 ,  A61K38/16 ,  A61K38/46 ,  A61K45/06 ,  A61P31/04 ,  C12N9/36

Abstract: The present disclosure relates to methods for restoring or augmenting bactericidal activity of an antibiotic in an organ or tissue in which pulmonary surfactant is present. More specifically, the present disclosure describes that inhibition of antibiotics due to environmental factors, such as the presence of pulmonary surfactant in an organ or tissue such as the respiratory epithelium can be sidestepped or overcome and the effectiveness of the antibiotic in that milieu restored or augmented by co-administration of an antibiotic and a lysin.

公开(公告)号：US12233162B2

公开(公告)日：2025-02-25

申请号：US17266904

申请日：2019-08-09

Applicant: The University of Greenwich

Inventor： Simon Richardson ,  Benedita Feron

IPC: A61K9/127 ,  A61K9/1271 ,  A61K9/1277 ,  A61K31/7105 ,  A61K38/46 ,  A61P31/14 ,  C12N9/12 ,  C12N15/113

Abstract: The invention relates to liposomes, methods of producing liposomes, and methods of loading cell-derived liposomes with cargo molecules. The invention extends to such liposomes per se, and to the use of these liposomes as cellular delivery systems for the delivery of biologically and therapeutically active payload molecules, such as small molecules, RNAi molecules (e.g. siRNA), bioactive proteins, genome editing tools (e.g. Cas9) and drugs into cells for treating a range of disorders. The liposomes may also be used in a range of diagnostic and theranostic applications. The invention extends to pharmaceutical compositions comprising such liposomes, including populations of extracellular vesicles (EV), exosomes and to fusion proteins.

公开(公告)号：US12220446B2

公开(公告)日：2025-02-11

申请号：US16620154

申请日：2018-06-08

Applicant: THE FIRST AFFILIATED HOSPITAL, SUN YAT-SEN UNIVERSITY

Inventor： Nu Zhang

IPC: C12N15/55 ,  A61K31/713 ,  A61K38/17 ,  A61K38/46 ,  A61K48/00 ,  C07K14/435 ,  C12N9/16 ,  C12Q1/68 ,  C12Q1/6886 ,  G01N33/574

Abstract: Provided are an upstream Open Reading Frame (uORF) of a Phosphatase and Tensin homolog (PTEN) gene and a protein coded by the uORF. A potential ORF of 138 bases (45aa-uORF) in the 5′UTR of the PTEN, coding an oligopeptide of 45 amino acids (named PTEN-45aa) plays an important role in the development and progression progress of tumors. Further provided are a new diagnostic and therapeutic method and a drug screening platform for PTEN expression regulation related diseases, in particular neuroglioma. Also provided is a polypeptide for treatment of PTEN expression regulation related diseases.

公开(公告)号：US20250043258A1

公开(公告)日：2025-02-06

申请号：US18496845

申请日：2023-10-28

Applicant: Sarfaraz K. Niazi ,  Matthias Magoola

Inventor： Sarfaraz K. Niazi ,  Matthias Magoola

IPC: C12N9/22 ,  A61K31/502 ,  A61K31/519 ,  A61K31/522 ,  A61K31/5386 ,  A61K31/551 ,  A61K31/7088 ,  A61K38/46 ,  C12N15/11 ,  C12N15/88

Abstract: A novel composition for treating cancer comprising of a gRNA-Cas9 complex capable of locating, binding, and causing a double-strand break of the gene that is prevented from repair by accompanying DNA repair inhibitors.

公开(公告)号：US12214056B2

公开(公告)日：2025-02-04

申请号：US16318745

申请日：2017-07-19

Applicant: Duke University

Inventor： Charles A. Gersbach ,  Sarina Madhavan ,  Christopher Nelson

IPC: A61K48/00 ,  A61K31/7105 ,  A61K38/46 ,  A61P21/00 ,  C07K14/47 ,  C12N9/22 ,  C12N15/11 ,  C12N15/113 ,  C12N15/90

Abstract: Disclosed herein are therapeutic applications of CRISPR/Cpf1-based genome editing.

公开(公告)号：US20250031737A1

公开(公告)日：2025-01-30

申请号：US18913589

申请日：2024-10-11

Applicant: Alcresta Therapeutics, Inc.

Inventor： Eric FIRST ,  David BROWN ,  Albert Archie STONE

IPC: A23L29/00 ,  A23L33/00 ,  A23L33/12 ,  A61J3/00 ,  A61J15/00 ,  A61K9/00 ,  A61K38/46 ,  A61K38/47 ,  A61K38/48 ,  A61M5/14 ,  A61M5/142 ,  A61M5/168 ,  C12N9/20 ,  C12N9/26 ,  C12N9/50

Abstract: Exemplary embodiments of the disclosure may be drawn to a device having an inlet and a chamber. Immobilized lipase, immobilized protease, and immobilized amylase may be contained within the chamber. The device may also include an outlet, wherein a flow path extends from the inlet, through the chamber, and to the outlet.

公开(公告)号：US20250000954A1

公开(公告)日：2025-01-02

申请号：US18754776

申请日：2024-06-26

Applicant: Boston Scientific Scimed, Inc.

Inventor： Heather Cirka ,  Yen-Hao Hsu ,  Marc Plourde ,  Joseph Thomas Delaney, JR. ,  Cristian Parisi

IPC: A61K38/46 ,  A61M5/178 ,  A61N5/10

Abstract: Systems for hydrogel hydrolysis as well as methods for hydrogel hydrolysis are disclosed. An example system may include a syringe barrel having a needle connector disposed thereon. A hydrogel hydrolysis material may be disposed in the syringe barrel. The hydrogel hydrolysis material may be configured to be injected into a hydrogel formed in the body of a patient in order to accelerate the hydrolysis of the hydrogel.

公开(公告)号：US12178858B2

公开(公告)日：2024-12-31

申请号：US17181066

申请日：2021-02-22

Applicant: JCR Pharmaceuticals Co., Ltd.

Inventor： Hidehito Yasukawa ,  Yuka Yamaguchi ,  Shinji Okabe

IPC: A61K38/46 ,  A61K9/19 ,  A61K47/02 ,  A61K47/10 ,  A61K47/26 ,  A61K47/34 ,  C07K14/705 ,  C07K16/28

Abstract: [Problem] To provide a pharmaceutical composition containing a fusion protein comprising an antibody and a lysosomal enzyme as an active ingredient, which is stable enough to permit its distribution to the market.
[Solution] A lyophilized formulation containing; a fusion protein comprising an antibody and a lysosomal enzyme as an active ingredient, and further containing a neutral salt, a disaccharide, a nonionic surfactant, and a buffer. Such a lyophilized formulation includes, for example, as an active ingredient, a fusion protein comprising an anti-transferrin receptor antibody and human iduronate-2-sulfatase, and further containing sodium chloride as the neutral salt, sucrose as the disaccharide, poloxamer as the nonionic surfactant, and phosphate buffer as the buffer.

公开(公告)号：US12178785B2

公开(公告)日：2024-12-31

申请号：US18502995

申请日：2023-11-06

Applicant: Alcresta Therapeutics, Inc.

Inventor： Alexey L. Margolin ,  Robert Gallotto ,  Bhami Shenoy

IPC: A23L29/00 ,  A23D7/01 ,  A23D9/013 ,  A23K20/158 ,  A23K50/30 ,  A23L33/00 ,  A23L33/115 ,  A23L33/12 ,  A61J15/00 ,  A61K9/00 ,  A61K31/202 ,  A61K38/46 ,  B65D1/02 ,  B65D41/02 ,  B65D81/32 ,  B65D85/72

Abstract: Nutritional formulas comprising long-chain polyunsaturated fatty acids (LC-PUFAs) are provided, along with methods and devices for preparing and/or administering nutritional formulas. In some embodiments, a percentage of the LC-PUFAs in the nutritional formula are in the form of monogiycerides and/or free fatty acids. In some embodiments, the nutritional formulas do not comprise added lipase. Also provided are methods for providing nutrition to a subject, methods for improving fat absorption, methods for improving cognitive ability, methods for preventing chronic lung disease, and methods for reducing the length of time a patient requires total parenteral nutrition.

公开(公告)号：US12173306B2

公开(公告)日：2024-12-24

申请号：US17217961

申请日：2021-03-30

Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human Services

Inventor： Stephen G. Kaler

IPC: A61K48/00 ,  A61K33/34 ,  A61K38/46 ,  A61P3/00 ,  A61P25/00 ,  C12N9/14 ,  C12N15/86

Abstract: Disclosed herein are codon-optimized nucleic acids encoding a reduced-size ATP7A protein. Also disclosed are vectors and recombinant viruses (such as recombinant adeno-associated viruses) including the codon-optimized nucleic acids encoding the reduced-size ATP7A protein and compositions including the disclosed vectors and viruses. Further disclosed herein are methods of treating copper transport disorders, for example by administering a disclosed nucleic acid, vector, or recombinant virus to a subject with a copper transport disorder, such as Menkes disease, occipital horn syndrome, or ATP7A-related distal motor neuropathy.